Sanofi Stock Euronext Paris
Stocks
SANNV
FR001400UEY9
Pharmaceuticals
OTC Markets Traded| Market Cap | 83.85B 94.09B 78.17B 71.16B 134B 9,064B 135B 944B 367B 4,622B 353B 346B 14,856B | P/E 2026 * |
11.1x | P/E 2027 * | 9.69x |
|---|---|---|---|---|---|
| Enterprise Value | 95.76B 107B 89.27B 81.26B 153B 10,351B 154B 1,078B 419B 5,278B 403B 395B 16,965B | EV / Sales 2026 * |
2.01x | EV / Sales 2027 * | 1.83x |
| Free-Float |
88.34% | Yield 2026 * |
6.08% | Yield 2027 * | 6.43% |
Last Transcript: Sanofi
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Paulo Fontoura
CTO | Chief Tech/Sci/R&D Officer | - | 2026-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 56 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 65 | 2020-04-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +3.51% | - | - | 95.48B | |
| +0.02% | -3.41% | +36.11% | +115.09% | 1,019B | |
| -1.21% | -6.74% | +34.08% | +62.64% | 617B | |
| +1.12% | +0.54% | +13.62% | +79.94% | 464B | |
| -3.30% | -6.21% | +56.45% | +36.58% | 356B | |
| +0.93% | -3.16% | +21.65% | +43.02% | 333B | |
| +0.12% | -2.77% | +10.70% | +32.97% | 267B | |
| -0.89% | -6.28% | -7.00% | +8.01% | 244B | |
| -0.01% | -2.81% | +35.28% | +51.82% | 218B | |
| -0.08% | -4.17% | +28.34% | +93.51% | 179B | |
| Average | +0.09% | -3.54% | +25.47% | +58.17% | 410.8B | |
| Weighted average by Cap. | +0.28% | -3.54% | +28.50% | +70.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.66B 53.48B 44.43B 40.45B 76.24B 5,152B 76.73B 537B 209B 2,627B 201B 196B 8,444B | 50.62B 56.8B 47.19B 42.96B 80.98B 5,472B 81.49B 570B 222B 2,790B 213B 209B 8,969B |
| Net income | 7.48B 8.4B 6.98B 6.35B 11.97B 809B 12.05B 84.28B 32.76B 412B 31.52B 30.84B 1,326B | 8.9B 9.99B 8.3B 7.56B 14.24B 962B 14.33B 100B 38.98B 491B 37.51B 36.69B 1,578B |
| Net Debt | 11.91B 13.36B 11.1B 10.11B 19.05B 1,287B 19.17B 134B 52.13B 656B 50.16B 49.07B 2,110B | 8.61B 9.66B 8.03B 7.31B 13.78B 931B 13.86B 96.99B 37.7B 475B 36.28B 35.49B 1,526B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
